about
Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field-Flow Fractionation/Multiangle Laser Light Scattering.A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption.In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation and Precipitation of Posaconazole.Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population.Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities.In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT.Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.Drug disposition before and after gastric bypass: fenofibrate and posaconazole.Gastrointestinal transfer: in vivo evaluation and implementation in in vitro and in silico predictive tools.Persistent Threats by Persistent Pollutants: Chemical Nature, Concerns and Future Policy Regarding PCBs-What Are We Heading For?Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs.Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS class 2b) in the gastrointestinal simulator (GIS): An in vitro-in silico-in vivo approach.Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion.Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans.Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK ModelFormulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded '21st Century BA/BE' projectLinking the Gastrointestinal Behavior of Ibuprofen with The Systemic Exposure Between and Within Humans - Part 1: Fasted StateMass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate-CO Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical SignificanceApplication of a Dynamic Fluid & pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlus™Supersaturation in human gastric fluidsExploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways AnalysesGastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approachIntegrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example IbuprofenIn vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration"Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development StrategyA Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVPLinking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed StateThe mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP groupTranslational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives
P50
Q35996590-4943348D-82E0-48DC-879A-8DE45A39C194Q38133189-DA4A954F-BF1C-48AA-80C8-25752857A190Q38620124-4F24BA44-8415-4BD1-9588-1503C37C6E12Q38815307-0738044A-FA13-41D5-94DB-88881A5220CEQ39028475-9A365931-4810-4420-8829-274BB16987F8Q39298938-6D41D148-0D38-4D4F-BF88-59A55137A3A3Q40907845-88452236-AAA4-415F-A5C8-EEEC39CD10C7Q42700900-AC70CEC2-0467-41E8-9AD8-FBEB754B5553Q44046190-F6479715-1B83-4562-B31D-880B3FDCF59DQ47769382-86D1C650-AFC9-416A-9D8F-15B8DDC31122Q47888842-9F7A28A6-E4F3-408E-9A71-57F9D021CC64Q49602376-2EB957FE-C8BC-4E98-A547-1711FF6196CCQ51284615-980D3791-DE01-4190-84B7-AB69A14C39B5Q53304153-B40D12D2-C993-4287-8446-6037CAE6EA2EQ57121425-80F42264-DFE2-4345-A14B-847D5BA610D1Q57160637-13B9E25F-DC9E-4FA8-B911-70BA44C96DB6Q58105559-F1D4C78F-F8F2-4A2E-9E8D-DB49E6E23DFBQ58611371-8B74A3C4-0910-4600-8D93-5A1491D74E80Q58617166-72BB40A9-32A9-41CC-A545-E8BE6508A18CQ59285510-78B93D28-CA7A-4882-AD0D-75E716278B21Q64090036-7F576BB3-05B1-4411-8B05-AE8535041682Q88950865-778E0B9E-C356-4F55-B5BC-7B047681A19BQ90191240-66B737EF-5420-49CD-9301-FDC4BC4788FDQ90720164-7F958B12-0EF3-4373-A92D-90570944B404Q92575904-933F3FB1-FBB2-4E1F-AB9B-6531DEA043BFQ92811541-95CB14E7-2B81-44ED-99A9-C244F2CC3981Q92996835-CF472BA2-69B6-4990-9912-4371A78965B5Q93028354-2E84CBCA-41E9-4AB1-81C1-341E076EB96EQ94673859-29DCDD4C-4504-46D0-AB34-5FC4B82E9E5D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bart Hens
@ast
Bart Hens
@en
Bart Hens
@es
Bart Hens
@nl
Bart Hens
@sl
type
label
Bart Hens
@ast
Bart Hens
@en
Bart Hens
@es
Bart Hens
@nl
Bart Hens
@sl
prefLabel
Bart Hens
@ast
Bart Hens
@en
Bart Hens
@es
Bart Hens
@nl
Bart Hens
@sl
P1053
O-6788-2017
P106
P21
P31
P3829
P3835
bart-hens2
P496
0000-0002-4229-9843